Sign In
Buy BBIO
$83.08
-2.81 (-3.27%)
At Close: Jul 13, 2026
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
12:25pm, Monday, 13'th Jul 2026
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset e
BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play
09:55am, Sunday, 12'th Jul 2026
BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and inte
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 10'th Jul 2026
PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genet
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
01:25pm, Friday, 10'th Jul 2026
BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
06:36am, Friday, 10'th Jul 2026
BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth
01:31pm, Wednesday, 08'th Jul 2026
BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.
BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts
01:25pm, Wednesday, 08'th Jul 2026
BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead
01:25pm, Wednesday, 08'th Jul 2026
BridgeBio Pharma BBIO has become a harder stock to judge after its sharp rare-disease run. Attruby is ramping quickly, yet the valuation already assumes a good deal of future success.
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
07:30am, Thursday, 02'nd Jul 2026
- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
07:30am, Wednesday, 01'st Jul 2026
- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% pr
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically sig
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:31pm, Tuesday, 23'rd Jun 2026
PALO ALTO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genet
PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused o
Mid-Day Stocks: Stocks are trading lower on Wednesday, as oil and yields move higher. Once again, it was "Welcome back, my friends to the show that never ends." On cue, the never-say-die stock market
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
07:30am, Wednesday, 27'th May 2026
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for tr
